沃森生物：收到呼吸道合胞病毒mRNA疫苗《药物临床试验批准通知书》

Core Viewpoint - Watson Bio, in collaboration with Fudan University, Shanghai Blue Magpie Biopharmaceutical Co., Ltd., and its subsidiaries, has received approval from the National Medical Products Administration for a clinical trial of an mRNA vaccine targeting respiratory syncytial virus [1] Group 1 - Watson Bio announced the joint development and clinical trial application for the respiratory syncytial virus mRNA vaccine [1] - The approval was granted by the National Medical Products Administration, indicating a significant step in the vaccine's development process [1] - The collaboration involves multiple entities, including academic and biopharmaceutical partners, highlighting a strategic alliance in vaccine research [1]